HomeCompareHJLI vs PLD

HJLI vs PLD: Dividend Comparison 2026

HJLI yields 19.27% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.84M in total portfolio value· pulled ahead in Year 5
10 years
HJLI
HJLI
● Live price
19.27%
Share price
$10.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.8K
Annual income
$6,227.54
Full HJLI calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — HJLI vs PLD

📍 PLD pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHJLIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HJLI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HJLI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HJLI
Annual income on $10K today (after 15% tax)
$1,637.76/yr
After 10yr DRIP, annual income (after tax)
$5,293.41/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,032,823.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HJLI + PLD for your $10,000?

HJLI: 50%PLD: 50%
100% PLD50/50100% HJLI
Portfolio after 10yr
$2.99M
Annual income
$2,378,476.36/yr
Blended yield
79.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

HJLI
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
14.9
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HJLI buys
0
PLD buys
0
No recent congressional trades found for HJLI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHJLIPLD
Forward yield19.27%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$69.8K$5.91M
Annual income after 10y$6,227.54$4,750,725.19
Total dividends collected$38.9K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: HJLI vs PLD ($10,000, DRIP)

YearHJLI PortfolioHJLI Income/yrPLD PortfolioPLD Income/yrGap
1$12,627$1,926.78$11,241$540.96+$1.4KHJLI
2$15,784$2,273.74$13,019$991.13+$2.8KHJLI
3$19,546$2,656.40$15,801$1,870.97+$3.7KHJLI
4$23,988$3,074.20$20,609$3,701.21+$3.4KHJLI
5← crossover$29,193$3,526.09$29,919$7,867.97$726.00PLD
6$35,247$4,010.50$50,631$18,617.74$15.4KPLD
7$42,240$4,525.40$105,528$51,352.20$63.3KPLD
8$50,265$5,068.41$287,364$174,449.42$237.1KPLD
9$59,421$5,636.78$1,081,760$774,280.77$1.02MPLD
10$69,808$6,227.54$5,908,209$4,750,725.19$5.84MPLD

HJLI vs PLD: Complete Analysis 2026

HJLIStock

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

Full HJLI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this HJLI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HJLI vs SCHDHJLI vs JEPIHJLI vs OHJLI vs KOHJLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.